BANGALORE, India and PARIS , October 29, 2014 /PRNewswire/ --
Infosys, a global leader in consulting, technology and outsourcing, today announced the launch of its Innovation in Retail Banking 2014 report.
- Third quarter 2014 earnings per share (diluted) increased 20.9% to $1.10 compared with the third quarter 2013 - Net income increased $21.292 million or 38.5% compared with the third quarter 2013
- Nonperforming assets remain low at 0.27% of third quarter average earning assets - Loans increased $3.186 billion or 51.5% compared with the third quarter 2013 - Deposits increased $4.558 billion or 36.6% compared with the third quarter 2013 - Dividend increased 13.5% to $0.2725 for the fourth quarter 2014 HOUSTON , Oct.
Praxair, Inc. (NYSE:PX) reported third-quarter net income of $477
million and diluted earnings per share of $1.62, 6% and 7% above the
prior year, respectively.*
Sales in the third quarter were $3,144 million, 4% above the prior year.
RALEIGH, NC--(Marketwired - October 29, 2014) - DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals with a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today petitioned the U.S. Food and Drug Administration (FDA) to amend the label for tamoxifen citrate and Soltamox ® (tamoxifen citrate), the only FDA-approved liquid bioequivalent of tamoxifen, by increasing the recommended duration of adjuvant therapy for women with estrogen receptor-positive breast cancer from five to 10 years.
By Barbara Kollmeyer, MarketWatch
MADRID (MarketWatch) -- Stock futures largely stuck to the flat line ahead of a decision from the Federal Open Market Committee, though technology stocks look set to see pressure as Facebook Inc. shares fell after results.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.